Precipio (PRPO) Proxy Filing summary

Executive summary

• Urgent request for shareholders and brokers to vote by 11 p.m. ET to ensure quorum for the annual meeting scheduled for June 13, 2024.

• Only 44% of shares have been voted; at least 50% is required to proceed with the meeting.

• Rescheduling the meeting due to lack of quorum could cost up to $100,000, compared to the current cost of less than $5,000.

• The company focuses on cancer diagnostics, aiming to reduce misdiagnoses and improve patient outcomes through proprietary technologies.

Voting matters and shareholder proposals

• Shareholders are urged to vote regardless of their stance to meet quorum and avoid costly adjournment.

Risk oversight and compliance

• Forward-looking statements highlight risks and uncertainties, with actual results potentially differing materially from projections.

• Investors are cautioned to review risk factors and management's discussion in recent SEC filings.